{"id":7701,"date":"2020-07-10T05:33:56","date_gmt":"2020-07-10T05:33:56","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/"},"modified":"2020-07-10T05:33:56","modified_gmt":"2020-07-10T05:33:56","slug":"nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/","title":{"rendered":"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui la cession pour un montant de 5 millions d\u2019euros du solde de sa participation dans VISUfarma, soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e en ophtalmologie, \u00e0 une filiale de son principal actionnaire, GHO Capital. Cette participation \u00e9tait constitu\u00e9e d&rsquo;actions d\u2019une soci\u00e9t\u00e9 britannique holding de VISUfarma et d\u2019obligations de VISUfarma B.V.<\/p>\n<p>\u201c<em>La r\u00e9alisation de notre participation dans VISUfarma par sa cession \u00e0 son principal actionnaire, GHO Capital, s\u2019inscrit dans notre strat\u00e9gie d\u2019avancement de notre pipeline R&amp;D de soumission de demandes d\u2019autorisation de mise sur le march\u00e9 pour nos deux principaux candidats m\u00e9dicaments, NCX 470 et NCX 4251. Cet accord, qui s\u2019ajoute \u00e0 l\u2019extension de notre collaboration avec Ocumension en mars, montre notre capacit\u00e9 \u00e0 garantir les ressources financi\u00e8res n\u00e9cessaires \u00e0 notre soci\u00e9t\u00e9 gr\u00e2ce \u00e0 nos multiples actifs<\/em>.\u201d a d\u00e9clar\u00e9 <strong>Gavin Spencer, Chief Business Officer de Nicox<\/strong>.<\/p>\n<p>Nicox a c\u00e9d\u00e9 son infrastructure commerciale europ\u00e9enne et internationale ainsi que certains actifs et droits \u00e0 VISUfarma en ao\u00fbt 2016. La transaction est conditionn\u00e9e \u00e0 certaines autorisations et devrait \u00eatre finalis\u00e9e le 23 juillet au plus tard.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui la cession pour un montant de 5 millions d\u2019euros du solde de sa participation dans VISUfarma, soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e en ophtalmologie, \u00e0 une filiale de son principal actionnaire, GHO Capital. Cette participation \u00e9tait constitu\u00e9e d&rsquo;actions d\u2019une [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7701","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui la cession pour un montant de 5 millions d\u2019euros du solde de sa participation dans VISUfarma, soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e en ophtalmologie, \u00e0 une filiale de son principal actionnaire, GHO Capital. Cette participation \u00e9tait constitu\u00e9e d&rsquo;actions d\u2019une [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-10T05:33:56+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma\",\"datePublished\":\"2020-07-10T05:33:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\\\/\"},\"wordCount\":224,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\\\/\",\"name\":\"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-07-10T05:33:56+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui la cession pour un montant de 5 millions d\u2019euros du solde de sa participation dans VISUfarma, soci\u00e9t\u00e9 pharmaceutique pan-europ\u00e9enne sp\u00e9cialis\u00e9e en ophtalmologie, \u00e0 une filiale de son principal actionnaire, GHO Capital. Cette participation \u00e9tait constitu\u00e9e d&rsquo;actions d\u2019une [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/","og_site_name":"Nicox","article_published_time":"2020-07-10T05:33:56+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/"},"author":{"name":"","@id":""},"headline":"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma","datePublished":"2020-07-10T05:33:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/"},"wordCount":224,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/","url":"https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/","name":"Nicox renforce sa position de tr\u00e9sorerie avec la cession de sa participation dans VISUfarma - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-07-10T05:33:56+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-renforce-sa-position-de-tresorerie-avec-la-cession-de-sa-participation-dans-visufarma-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7701"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7701\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}